LEADERSHIP

Kevin Lee, Ph.D., MBA (CEO)

Kevin Lee, Ph.D., MBA, is Chief Executive Officer of Bicycle Therapeutics. Under his leadership, Bicycle Therapeutics’ strategy has become focused on developing novel treatments for oncology using Bicycle Drug Conjugates® to selectively deliver toxins to tumours. Dr. Lee joins Bicycle Therapeutics from Pfizer, where he served as Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programs across the full spectrum of research and development, established Pfizer’s Rare Disease strategy, conceptualized and implemented the company’s Gene Therapy strategy with the creation of the Genetic Medicine Institute and also founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GSK and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, Dr. Lee lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions.

Dr. Lee studied Pharmaceutical Sciences at Nottingham University followed by a Ph.D. in Pharmacology at Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research unit in Cambridge, U.K. Dr. Lee is an author on over 100 peer-reviewed scientific publications, has an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick.

 

Ros Deegan, MBA (President and CBO, Bicycle Therapeutics Inc.)

Ros Deegan, MBA, is President and Chief Business Officer of Bicycle Therapeutics Inc., the U.S. subsidiary of Bicycle Therapeutics. Prior to joining Bicycle, Ms. Deegan most recently served on the senior leadership team at Trevena, Inc. as Senior Vice President, Business Development and Operations and previously held the role of Head of Finance and Operations. While at Trevena, she was responsible for start-up operations, negotiating a significant option and license agreement with Forest Laboratories, Inc., and leading finance and human resources through to the company’s first S-1 filing with the Securities and Exchange Commission. During her tenure, the company moved three programs into the clinic, and raised over $200 million in private and public financings. Prior to joining Trevena, Ms. Deegan served as Director of Business Development at GSK in the U.S., leading transactions for the virtual immuno-inflammation group. Prior to that, she served as the Director of Operations for the Center of Excellence for External Drug Discovery (CEEDD), as Marketing Manager for GSK’s U.K. launch of Bonviva for post-menopausal osteoporosis and in Business Development.

Ms. Deegan holds a first class degree from Cambridge University and received her MBA with distinction from INSEAD.

 

 

Andrew Muncey (CFO)

Andrew Muncey is Chief Financial Officer of Bicycle Therapeutics. Mr. Muncey brings over 30 years of experience in finance and management. He was previously Co-founder and Chief Financial Officer of Acacia Pharma, prior to which he was the Chief Executive Officer of Amura Therapeutics. He has also been Chief Financial Officer or Finance Director of several healthcare companies, including Kymab, Lorantis, Mission Therapeutics and Virttu Biologics. Mr. Muncey has raised significant amounts of equity and debt funding, including $200 million of private equity, and completed acquisitions, disposals and restructuring deals in the healthcare market. He has over 15 years of corporate finance and capital markets experience from PricewaterhouseCoopers and Swiss Bank Corporation.

 

 

Michael Skynner, Ph.D. (VP Operations)

Michael Skynner, Ph.D., is Vice President of Operations at Bicycle Therapeutics. He joined Bicycle Therapeutics from Pfizer where he led rare disease efforts in Europe and founded and ran the Pfizer Rare Disease Consortium (RDC). The RDC was an innovative agreement between Pfizer and 20 leading U.K. universities that created research partnerships between Pfizer, academic researchers and patient groups to develop new therapies for rare and orphan diseases using a new collaborative paradigm. As part of those activities he also established Pfizer’s Genetic Medicine Institute, a bespoke research unit in central London embedded within the U.K. gene therapy academic community. Previously, he established a Discovery Performance Unit at GSK focused on developing therapeutics targeting inflammatory kinases using an externalised and partnered model with leading European biotechnology companies. In his time at GSK he successfully advanced multiple molecules from screening into clinical trials. Prior to GSK he co-founded a successful biotech start-up company, Cambridge Biotechnology Ltd (CBT), which specialised in developing small molecule and peptide therapeutics for inflammation and metabolic disease. CBT was sold to Swedish Orphan Biovitrum. 

Dr. Skynner obtained his Ph.D. in Biochemistry at Imperial College and is an author on over 30 peer-reviewed scientific publications.

 

 

Alan Watt, Ph.D., MBA (Interim CSO and Head of Therapeutics)

Alan Watt, Ph.D., MBA, is interim CSO and Head of Therapeutics at Bicycle Therapeutics. He brings over 30 years of experience in drug discovery and development in both the pharmaceutical and biotechnology sectors. Previously, he established Xenovium to work in partnership with pharmaceutical and biotechnology clients delivering drug discovery and development projects. He also served as Chief Operating Officer/Executive Vice President of R&D for Trident Pharmaceuticals, a biotechnology company developing an immunomodulatory biologic drug. Prior to that, he served as Vice President of Therapeutics at Cellzome UK where he successfully led the company’s immunology drug discovery efforts, delivering a number of kinase inhibitor drug candidates and contributing to the successful exit to GSK. He also established and led the Pattern Recognition Receptor Discovery Performance Unit within GSK’s Immuno-Inflammation Centre of Excellence for Drug Discovery (CEDD), prior to which he was Head of Preclinical Development for the Neurology CEDD. He also previously served as Head of Drug Metabolism and Head of In Vivo Pharmacology at Merck.

Dr. Watt holds a Ph.D. in Drug Metabolism, an MBA from the Open Business School, a B.Sc. in Chemistry, and has over 50 peer-reviewed scientific publications. Dr. Watt also works in the voluntary sector as a Trustee of the Babraham Institute (BI), an independent charitable life sciences institute involved in biomedical research and as a Director of Babraham Institute Enterprise, the commercial arm of the Babraham Institute.